This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lucchinetti, C. Articles by Bruck, W. Search for Related Content PubMed PubMed Citation Articles by Lucchinetti, C. Articles by Bruck, W. Social Bookmarking                         What's this?

The pathology of primary progressive multiple sclerosis

Department of Neurology, Mayo Clinic, Rochester, MN, USA, lucchinetti.claudia{at}mayo.edu

Wolfgang Bruck

Department of Neuropathology, University of Gottingen, Gottingen, Germany

The patho logical hallmark of chronic multiple sclerosis includes focal demyelination, gliosis, inflammation and axonal injury. There is limited information on whether these pathological features differ across the clinical pheno types of the disease (relapsing-remitting, secondary progressive, and primary progressive). This review will focus on the patho logical aspects of PPMS and pathogenic implications. A better understanding of the differences in PPMS pathology and patho genesis will lead to more effective treatment strategies.

Key Words: axons • multiple sclerosis • myelin • oligodendrocytes • pathology

Multiple Sclerosis, Vol. 10, No. 3 suppl, S23-S30 (2004)
DOI: 10.1191/1352458504ms1027oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				X. Montalban, J. Sastre-Garriga, M. Filippi, Z. Khaleeli, N. Tellez, M. Vellinga, C. Tur, B. Brochet, F. Barkhof, M. Rovaris, et al. Primary progressive multiple sclerosis diagnostic criteria: a reappraisal Multiple Sclerosis, December 1, 2009; 15(12): 1459 - 1465. [Abstract] [PDF]

				X. Montalban, J. Sastre-Garriga, M. Tintore, L. Brieva, F. Aymerich, J. Rio, J. Porcel, C. Borras, C. Nos, and A. Rovira A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis Multiple Sclerosis, October 1, 2009; 15(10): 1195 - 1205. [Abstract] [PDF]

				C. Di Perri, M. Battaglini, M. L. Stromillo, M. L. Bartolozzi, L. Guidi, A. Federico, and N. De Stefano Voxel-Based Assessment of Differences in Damage and Distribution of White Matter Lesions Between Patients With Primary Progressive and Relapsing-Remitting Multiple Sclerosis Arch Neurol, February 1, 2008; 65(2): 236 - 243. [Abstract] [Full Text] [PDF]

				S. Chandran, D. Hunt, A. Joannides, C. Zhao, A. Compston, and R. J.M Franklin Myelin repair: the role of stem and precursor cells in multiple sclerosis Phil Trans R Soc B, January 12, 2008; 363(1489): 171 - 183. [Abstract] [Full Text] [PDF]

				Z Khaleeli, J Sastre-Garriga, O Ciccarelli, D H Miller, and A J Thompson Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis J. Neurol. Neurosurg. Psychiatry, October 1, 2007; 78(10): 1076 - 1082. [Abstract] [Full Text] [PDF]

				L. F. Barcellos, S. Sawcer, P. P. Ramsay, S. E. Baranzini, G. Thomson, F. Briggs, B. C.A. Cree, A. B. Begovich, P. Villoslada, X. Montalban, et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis Hum. Mol. Genet., September 15, 2006; 15(18): 2813 - 2824. [Abstract] [Full Text] [PDF]

				R. M. Burwick, P. P. Ramsay, J. L. Haines, S. L. Hauser, J. R. Oksenberg, M. A. Pericak-Vance, S. Schmidt, A. Compston, S. Sawcer, R. Cittadella, et al. APOE epsilon variation in multiple sclerosis susceptibility and disease severity: Some answers Neurology, May 9, 2006; 66(9): 1373 - 1383. [Abstract] [Full Text] [PDF]